CN102015682B - 作为肾素抑制剂的3,4-取代的哌啶衍生物 - Google Patents
作为肾素抑制剂的3,4-取代的哌啶衍生物 Download PDFInfo
- Publication number
- CN102015682B CN102015682B CN200980116219.5A CN200980116219A CN102015682B CN 102015682 B CN102015682 B CN 102015682B CN 200980116219 A CN200980116219 A CN 200980116219A CN 102015682 B CN102015682 B CN 102015682B
- Authority
- CN
- China
- Prior art keywords
- methyl
- equiv
- amine
- vacuo
- etoac
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *Cc1ncccc1 Chemical compound *Cc1ncccc1 0.000 description 15
- FTWUUUNPZDCRRI-UHFFFAOYSA-N CC1=C=CCC1 Chemical compound CC1=C=CCC1 FTWUUUNPZDCRRI-UHFFFAOYSA-N 0.000 description 1
- CFPVAVIVMPQWCL-UHFFFAOYSA-N CN(C=CC(C(CCNC1)C1C(N(Cc1cc(Br)cc(CCCOC)c1)C1CC1)=O)=C1)C1=O Chemical compound CN(C=CC(C(CCNC1)C1C(N(Cc1cc(Br)cc(CCCOC)c1)C1CC1)=O)=C1)C1=O CFPVAVIVMPQWCL-UHFFFAOYSA-N 0.000 description 1
- LSHIKKCNCJHIFH-BBMPLOMVSA-N CN(C=CC(C(CCNC1)[C@H]1C(N(Cc1c[n](Cc2cnccc2)c2c1c(F)ccc2)C1CC1)=O)=C1)C1=O Chemical compound CN(C=CC(C(CCNC1)[C@H]1C(N(Cc1c[n](Cc2cnccc2)c2c1c(F)ccc2)C1CC1)=O)=C1)C1=O LSHIKKCNCJHIFH-BBMPLOMVSA-N 0.000 description 1
- BNPSUYFRQIHFCF-KEKNWZKVSA-N CN(C=CC(C(CCNC1)[C@H]1C(N(Cc1cc(OCCOC)ccc1Cl)C1CC1)=O)=C1)C1=O Chemical compound CN(C=CC(C(CCNC1)[C@H]1C(N(Cc1cc(OCCOC)ccc1Cl)C1CC1)=O)=C1)C1=O BNPSUYFRQIHFCF-KEKNWZKVSA-N 0.000 description 1
- FTXZURWKZWLFGZ-AVJYQCBHSA-N CN(C=CC([C@@H](CCNC1)C1C(N(Cc1cc(CCOC)cc2ccccc12)C1CC1)=O)=C1)C1=O Chemical compound CN(C=CC([C@@H](CCNC1)C1C(N(Cc1cc(CCOC)cc2ccccc12)C1CC1)=O)=C1)C1=O FTXZURWKZWLFGZ-AVJYQCBHSA-N 0.000 description 1
- DIHPWORWCZGCRW-UHFFFAOYSA-N COCCCc1cc(CN(C2CC2)C(C(CNCC2)C2C(C=CN2N)=CC2=O)=O)cc(-c2ccccc2)c1 Chemical compound COCCCc1cc(CN(C2CC2)C(C(CNCC2)C2C(C=CN2N)=CC2=O)=O)cc(-c2ccccc2)c1 DIHPWORWCZGCRW-UHFFFAOYSA-N 0.000 description 1
- PVURREOJPFBWAH-UHFFFAOYSA-N Cc(c(C(c1cc(F)ccc1)O)cc(CN(C1CC1)C(C(CNCC1)C1C(C=CN1C)=CC1=O)=O)c1)c1Br Chemical compound Cc(c(C(c1cc(F)ccc1)O)cc(CN(C1CC1)C(C(CNCC1)C1C(C=CN1C)=CC1=O)=O)c1)c1Br PVURREOJPFBWAH-UHFFFAOYSA-N 0.000 description 1
- NVGLYUJBWWGNJS-UHFFFAOYSA-M S[Cs]Cc1cccnc1 Chemical compound S[Cs]Cc1cccnc1 NVGLYUJBWWGNJS-UHFFFAOYSA-M 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pregnancy & Childbirth (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12652908P | 2008-05-05 | 2008-05-05 | |
| US61/126529 | 2008-05-05 | ||
| US18830308P | 2008-08-07 | 2008-08-07 | |
| US61/188303 | 2008-08-07 | ||
| PCT/CA2009/000611 WO2009135299A1 (en) | 2008-05-05 | 2009-05-04 | 3, 4 - substituted piperidine derivatives as renin inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102015682A CN102015682A (zh) | 2011-04-13 |
| CN102015682B true CN102015682B (zh) | 2014-07-16 |
Family
ID=41264366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200980116219.5A Expired - Fee Related CN102015682B (zh) | 2008-05-05 | 2009-05-04 | 作为肾素抑制剂的3,4-取代的哌啶衍生物 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8889714B2 (enExample) |
| EP (1) | EP2274295B1 (enExample) |
| JP (3) | JP4790871B2 (enExample) |
| KR (2) | KR101403311B1 (enExample) |
| CN (1) | CN102015682B (enExample) |
| AU (1) | AU2009243875B2 (enExample) |
| BR (1) | BRPI0912388A2 (enExample) |
| CA (1) | CA2722734C (enExample) |
| CO (1) | CO6311081A2 (enExample) |
| CR (1) | CR11809A (enExample) |
| DO (1) | DOP2010000329A (enExample) |
| EA (1) | EA020853B1 (enExample) |
| ES (1) | ES2548134T3 (enExample) |
| IL (1) | IL208467A (enExample) |
| MA (1) | MA32296B1 (enExample) |
| MX (1) | MX2010012067A (enExample) |
| MY (1) | MY152042A (enExample) |
| NI (1) | NI201000188A (enExample) |
| NZ (1) | NZ589019A (enExample) |
| PL (1) | PL2274295T3 (enExample) |
| SG (1) | SG192543A1 (enExample) |
| SV (1) | SV2010003723A (enExample) |
| WO (1) | WO2009135299A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5627574B2 (ja) | 2008-06-03 | 2014-11-19 | インターミューン， インコーポレイテッド | 炎症性および線維性疾患を治療するための化合物および方法 |
| AU2009326797B2 (en) * | 2008-12-10 | 2012-12-13 | Merck Canada Inc. | 3,4 - substituted piperidine derivatives as renin inhibitors |
| TWI562977B (en) * | 2010-11-05 | 2016-12-21 | Bayer Ip Gmbh | Process for the preparation of substituted n-(benzyl)cyclopropanamines by imine hydrogenation |
| UA112897C2 (uk) * | 2012-05-09 | 2016-11-10 | Байєр Фарма Акцієнгезелльшафт | Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| US10233195B2 (en) | 2014-04-02 | 2019-03-19 | Intermune, Inc. | Anti-fibrotic pyridinones |
| CN107602381B (zh) * | 2017-09-11 | 2021-03-16 | 陕西莱特光电材料股份有限公司 | 一种萘甲酸酯类衍生物及其制备方法 |
| CN108033876A (zh) * | 2017-12-20 | 2018-05-15 | 江汉大学 | 一种5-溴-2-氯苯甲醛的制备方法 |
| WO2020109039A1 (en) | 2018-11-28 | 2020-06-04 | Basf Se | Pesticidal compounds |
| CN115443267B (zh) | 2020-04-28 | 2025-09-05 | 巴斯夫欧洲公司 | 杀害虫化合物 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006128659A2 (en) * | 2005-05-31 | 2006-12-07 | Novartis Ag | Piperazine derivative renin inhibitors. |
| CN101014594A (zh) * | 2004-07-09 | 2007-08-08 | 斯皮德尔实验股份公司 | 哌啶衍生物作为肾素抑制剂 |
| CN101094848A (zh) * | 2004-12-30 | 2007-12-26 | 诺瓦提斯公司 | 有机化合物 |
| CN101103002A (zh) * | 2005-01-14 | 2008-01-09 | 诺瓦提斯公司 | 3,4(,5)-取代的四氢吡啶 |
| CN101133025A (zh) * | 2005-03-09 | 2008-02-27 | 诺瓦提斯公司 | 有机化合物 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5380758A (en) * | 1991-03-29 | 1995-01-10 | Brigham And Women's Hospital | S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof |
| US5703073A (en) * | 1995-04-19 | 1997-12-30 | Nitromed, Inc. | Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs |
| PL193686B1 (pl) | 1995-09-07 | 2007-03-30 | Hoffmann La Roche | Pochodne piperydyny, środki lecznicze zawierającepochodne piperydyny, sposoby wytwarzania tych pochodnych oraz zastosowanie pochodnych |
| US5994294A (en) * | 1996-02-02 | 1999-11-30 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses |
| WO1998019672A1 (en) | 1996-11-01 | 1998-05-14 | Nitromed Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
| IT1295694B1 (it) | 1996-11-14 | 1999-05-27 | Nicox Sa | Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica |
| IT1292426B1 (it) * | 1997-06-27 | 1999-02-08 | Nicox Sa | Sali nitrati di ace-inibitori |
| EP1415987B1 (en) | 2000-10-20 | 2007-02-28 | Eisai R&D Management Co., Ltd. | Nitrogenous aromatic ring compounds as anti cancer agents |
| CA2483241C (en) | 2002-04-29 | 2011-05-31 | Actelion Pharmaceuticals Ltd | Novel diazabicyclononene derivatives |
| US20060009497A1 (en) | 2002-06-27 | 2006-01-12 | Actelion Pharmaceuticals, Ltd. | Novel tetrahydropyridine derivatives as renin inhibitors |
| US20040204455A1 (en) | 2003-04-10 | 2004-10-14 | Cody Wayne Livingston | Piperidine derivative rennin inhibitors |
| US20060217371A1 (en) | 2003-04-28 | 2006-09-28 | Olivier Bezencon | Diazabicyclononene and tetrahydropyriddine derivatives as renin inhibitors |
| CN1972912A (zh) | 2003-04-29 | 2007-05-30 | 埃科特莱茵药品有限公司 | 新型3,4－二取代的1,2,3,6－四氢吡啶衍生物 |
| BRPI0409818A (pt) | 2003-04-30 | 2006-05-09 | Actelion Pharmaceuticals Ltd | compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos |
| US20060205768A1 (en) | 2003-04-30 | 2006-09-14 | Olivier Bezencon | Tropane derivatives and their use as ace inhibitors |
| CN1780663A (zh) | 2003-04-30 | 2006-05-31 | 埃科特莱茵药品有限公司 | 作为肾素抑制剂的新型3－位具有杂原子的9－氮杂双环壬烯衍生物 |
| MXPA05011711A (es) | 2003-05-02 | 2006-01-23 | Actelion Pharmaceuticals Ltd | Derivados de diazabiciclononeno. |
| TW200513461A (en) | 2003-10-01 | 2005-04-16 | Speedel Experimenta Ag | Organische verbindungen |
| CN1863773A (zh) | 2003-10-09 | 2006-11-15 | 埃科特莱茵药品有限公司 | 四氢吡啶衍生物 |
| WO2005040165A1 (en) | 2003-10-13 | 2005-05-06 | Actelion Pharmaceuticals Ltd | Diazabicyclononene derivatives and their use as renin inhibitors |
| US20070135405A1 (en) | 2003-10-23 | 2007-06-14 | Olivier Bezencon | Novel diazabicyclononene and tetrahydropyridine derivatives with a new polar side-chain |
| CA2547547A1 (en) | 2003-12-05 | 2005-06-16 | Actelion Pharmaceuticals Ltd | Diazabicyclononene derivatives and their use as renin inhibitors |
| JP2007513107A (ja) | 2003-12-05 | 2007-05-24 | アクテリオン ファマシューティカルズ リミテッド | ジアザビシクロノネンおよび新側鎖を有するテトラヒドロピリジン誘導体 |
| WO2006021401A2 (en) | 2004-08-25 | 2006-03-02 | Actelion Pharmaceuticals Ltd | Bicylononene derivatives |
| AU2005276624B2 (en) | 2004-08-25 | 2011-09-29 | Actelion Pharmaceuticals Ltd. | Bicyclononene derivatives as renin inhibitors |
| WO2006021399A2 (en) | 2004-08-25 | 2006-03-02 | Actelion Pharmaceuticals Ltd | Azabicyclononene derivatives as renin inhibitors |
| WO2006021403A1 (en) | 2004-08-25 | 2006-03-02 | Actelion Pharmaceuticals Ltd | Bicyclononene derivatives |
| WO2006058546A1 (en) | 2004-12-01 | 2006-06-08 | Actelion Pharmaceuticals Ltd | Novel lactame derivatives as renin inhibitors |
| AR052263A1 (es) | 2004-12-08 | 2007-03-07 | Actelion Pharmaceuticals Ltd | Derivado de diazabiciclononeno |
| WO2006063610A1 (en) | 2004-12-17 | 2006-06-22 | Actelion Pharmaceuticals Ltd | Heteroaryl substituted diazabicyclononene derivatives |
| CA2595986A1 (en) | 2005-01-28 | 2006-08-03 | Actelion Pharmaceuticals Ltd | 7-{4-[2-(2,6-dichlor0-4-methylphenoxy)-ethoxy]phenyl}-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dimethylbenzyl)amides as inhibitors of renin for the treatment of hypertension |
| WO2006092268A1 (en) | 2005-03-02 | 2006-09-08 | Actelion Pharmaceuticals Ltd | Bicyclic five-membered heteroaryl derivatives and their use as renin inhibitors |
| AR055756A1 (es) | 2005-03-31 | 2007-09-05 | Speedel Experimenta Ag | Piperidinas sustituidas; procesos de preparacion y su uso como medicamentos |
| JP2008535825A (ja) | 2005-03-31 | 2008-09-04 | シュペーデル・エクスペリメンタ・アーゲー | レニン阻害剤としての３，４，５−置換ピペリジン |
| GB0510810D0 (en) | 2005-05-26 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7799805B2 (en) | 2005-05-27 | 2010-09-21 | Actelion Pharmaceuticals Ltd. | Piperidine carboxylic acid amide derivatives |
| WO2006131884A2 (en) | 2005-06-07 | 2006-12-14 | Actelion Pharmaceuticals Ltd | Thiazole substituted diazabicyclononane or-nonene derivatives as renin inhibitors |
| AU2006272348B2 (en) | 2005-07-22 | 2011-06-16 | Merck Frosst Canada Ltd | Renin inhibitors |
| WO2007034406A1 (en) | 2005-09-22 | 2007-03-29 | Actelion Pharmaceuticals Ltd | Pyrrolidine-3-carboxylic acid amide derivatives and their use as inhibitors of renin |
| WO2007034445A2 (en) | 2005-09-26 | 2007-03-29 | Actelion Pharmaceuticals Ltd | Novel piperazine derivatives as renin inhibitors for cardiovascular events and renal insufficiency |
| WO2007049224A1 (en) | 2005-10-25 | 2007-05-03 | Actelion Pharmaceuticals Ltd | Novel hexahydro- or octahydro-cyclopenta[c]pyrrole derivatives |
| NZ569135A (en) | 2005-12-30 | 2011-08-26 | Novartis Ag | 3,5-Substituted piperidine compounds as renin inhibitors |
| EP1816122A3 (en) * | 2006-01-19 | 2007-09-19 | Speedel Experimenta AG | 3,4,5-substituted piperidines as therapeutic compounds |
| KR20080091273A (ko) | 2006-02-02 | 2008-10-09 | 액테리온 파마슈티칼 리미티드 | 레닌 저해제로서의 2차 아민 |
| BRPI0708487A2 (pt) | 2006-03-03 | 2011-05-31 | Actelion Pharmaceuticals Ltd | composto, composição farmacêutica que o compreende e seu uso |
| CL2007000595A1 (es) | 2006-03-08 | 2008-01-04 | Actelion Pharmaceuticals Ltd | Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras. |
| JP2010503682A (ja) | 2006-09-18 | 2010-02-04 | ビテ ファーマシューティカルズ， インコーポレイテッド | レニン阻害剤としてのピペリジン誘導体 |
| AU2007321671A1 (en) * | 2006-11-17 | 2008-05-22 | Merck Frosst Canada Ltd. | Renin inhibitors |
| CA2688057A1 (en) * | 2007-05-24 | 2008-11-27 | Merck Frosst Canada Ltd. | Novel case of renin inhibitors |
| JP2010535716A (ja) | 2007-08-07 | 2010-11-25 | メルク フロスト カナダ リミテツド | レニン阻害剤 |
| EP2229363A4 (en) * | 2007-12-04 | 2010-12-15 | Merck Frosst Canada Ltd | Renin Inhibitors |
| AU2009250299A1 (en) | 2008-05-22 | 2009-11-26 | Merck Frosst Canada Ltd | 3, 4 - substituted piperidine derivatives as renin inhibitors |
| US20120190701A1 (en) | 2009-08-18 | 2012-07-26 | Merck Sharp & Dohme Corp. | Renin inhibitors |
-
2009
- 2009-05-04 NZ NZ589019A patent/NZ589019A/xx not_active IP Right Cessation
- 2009-05-04 AU AU2009243875A patent/AU2009243875B2/en not_active Ceased
- 2009-05-04 JP JP2011507765A patent/JP4790871B2/ja not_active Expired - Fee Related
- 2009-05-04 KR KR1020107024856A patent/KR101403311B1/ko not_active Expired - Fee Related
- 2009-05-04 MY MYPI20105036 patent/MY152042A/en unknown
- 2009-05-04 SG SG2013055702A patent/SG192543A1/en unknown
- 2009-05-04 BR BRPI0912388A patent/BRPI0912388A2/pt not_active Application Discontinuation
- 2009-05-04 CN CN200980116219.5A patent/CN102015682B/zh not_active Expired - Fee Related
- 2009-05-04 WO PCT/CA2009/000611 patent/WO2009135299A1/en not_active Ceased
- 2009-05-04 ES ES09741617.6T patent/ES2548134T3/es active Active
- 2009-05-04 EA EA201071269A patent/EA020853B1/ru not_active IP Right Cessation
- 2009-05-04 KR KR1020137003332A patent/KR20130029116A/ko not_active Withdrawn
- 2009-05-04 US US12/990,927 patent/US8889714B2/en not_active Expired - Fee Related
- 2009-05-04 PL PL09741617T patent/PL2274295T3/pl unknown
- 2009-05-04 MX MX2010012067A patent/MX2010012067A/es active IP Right Grant
- 2009-05-04 EP EP09741617.6A patent/EP2274295B1/en active Active
- 2009-05-04 CA CA2722734A patent/CA2722734C/en not_active Expired - Fee Related
-
2010
- 2010-10-04 IL IL208467A patent/IL208467A/en not_active IP Right Cessation
- 2010-11-03 DO DO2010000329A patent/DOP2010000329A/es unknown
- 2010-11-04 SV SV2010003723A patent/SV2010003723A/es not_active Application Discontinuation
- 2010-11-05 NI NI201000188A patent/NI201000188A/es unknown
- 2010-11-11 MA MA33335A patent/MA32296B1/fr unknown
- 2010-11-11 CO CO10141827A patent/CO6311081A2/es not_active Application Discontinuation
- 2010-11-24 CR CR11809A patent/CR11809A/es not_active Application Discontinuation
-
2011
- 2011-06-01 JP JP2011123057A patent/JP5653842B2/ja not_active Expired - Fee Related
- 2011-06-01 JP JP2011123054A patent/JP5587246B2/ja not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101014594A (zh) * | 2004-07-09 | 2007-08-08 | 斯皮德尔实验股份公司 | 哌啶衍生物作为肾素抑制剂 |
| CN101094848A (zh) * | 2004-12-30 | 2007-12-26 | 诺瓦提斯公司 | 有机化合物 |
| CN101103002A (zh) * | 2005-01-14 | 2008-01-09 | 诺瓦提斯公司 | 3,4(,5)-取代的四氢吡啶 |
| CN101133025A (zh) * | 2005-03-09 | 2008-02-27 | 诺瓦提斯公司 | 有机化合物 |
| WO2006128659A2 (en) * | 2005-05-31 | 2006-12-07 | Novartis Ag | Piperazine derivative renin inhibitors. |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5653842B2 (ja) | レニン阻害剤としての３，４−置換ピペリジン誘導体 | |
| AU2009247262B2 (en) | Amide compound | |
| KR101214665B1 (ko) | 트리아졸 유도체 또는 그의 염 | |
| CN104822680B (zh) | 咪唑并吡啶化合物 | |
| TWI491595B (zh) | 作為香草類化合物受體之配體之經取代苯基尿素及苯基醯胺 | |
| KR102496404B1 (ko) | 혈장 칼리크레인의 저해제로서의 n-((het)아릴메틸)-헤테로아릴-카르복사미드 화합물 | |
| TWI353834B (en) | Aryl- and heteroarylpiperidinecarboxylate derivati | |
| JP2011520924A (ja) | レニン阻害剤としての３，４−置換ピペリジン誘導体 | |
| CN1434806A (zh) | 取代的咪唑神经肽yy5受体拮抗剂 | |
| JPWO2012036278A1 (ja) | グリシントランスポーター阻害物質 | |
| JP2012511514A (ja) | レニン阻害剤としての３，４−置換ピペリジン誘導体 | |
| TWI472524B (zh) | 腎素抑制劑 | |
| JP2025518047A (ja) | ＴＲＰＭ３媒介性障害を治療するためのピラゾロ［１，５－ａ］ピリジン誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: Quebec Applicant after: Merck Canada Inc. Applicant after: Merck Sharp & Dohme Address before: Quebec Applicant before: Merck Frosst Canada Ltd. Applicant before: Merck Sharp & Dohme |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: MERCK FROSST CANADA LTD. TO: MERCK (CANADA) CO., LTD. |
|
| ASS | Succession or assignment of patent right |
Owner name: ACTELION PHARMACEUTICALS LTD. Free format text: FORMER OWNER: MERCK (CANADA) CO., LTD. Effective date: 20131016 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20131016 Address after: Swiss Al Sewell Applicant after: Actelion Pharmaceuticals Ltd. Applicant after: Merck Sharp & Dohme Address before: Quebec Applicant before: Merck Canada Inc. Applicant before: Merck Sharp & Dohme |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140716 Termination date: 20190504 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |